Healthcare
Merck’s former chief executive officer and current executive chairman, Kenneth Frazier, has stepped down from his post at the pharmaceutical company to join venture capital firm General Catalyst as its newest chairman of health assurance initiatives.
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories.
Total payment amounts are contingent on the number of governments that will agree to suspend their lawsuits as part of the deal.
WHO Investigators have attempted to return to the Wuhan lab to find the origins of the novel coronavirus but are now being blocked by the Chinese government.
American health authorities have a dilemma. On one hand, COVID-19 booster shots for immunocompromised patients dramatically increase their immune response. On the other, in many parts of the world only a tiny fraction of the population have received even one dose of any COVID-19 vaccine. So, who should get the vaccines?
Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) is facing yet another obstacle as at least six affiliates of Blue Cross Blue Shield likely won’t cover the drug.
Senator Charles Schumer unveiled draft legislation that would decriminalize cannabis and expunge federal sentences associated with the drug, but it likely faces an uphill battle.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The CMA said some pharmaceutical firms charge the NHS with excessively high prices for hydrocortisone tablets and paid off potential competitors to stay out of the market.
Biden calls out the Health and Human Services department to submit a plan in the next 45 days to combat excessive drug prices and enhance domestic pharmaceutical supply chains.
PRESS RELEASES